A new drug for Alzheimer's disease, lecanemab, has shown a modest ability to slow cognitive decline, offering a new glimmer of hope for patients. However, the treatment comes with significant risks, including the potential for brain swelling and bleeding. It also carries a high price tag and requires frequent infusions and monitoring. This has sparked a debate among doctors and patients about whether the drug's benefits outweigh its risks and costs, highlighting the difficult decisions facing those affected by the disease.
